

#### RASF6 Antibody (C-term) Blocking peptide Synthetic peptide

Catalog # BP10404b

## Specification

# **RASF6 Antibody (C-term) Blocking peptide - Product Information**

Primary Accession Other Accession <u>Q6ZTQ3</u> <u>NP\_803876.1, NP\_958834.1</u>

### **RASF6** Antibody (C-term) Blocking peptide - Additional Information

Gene ID 166824

**Other Names** Ras association domain-containing protein 6, RASSF6

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

**Storage** Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

**Precautions** This product is for research use only. Not for use in diagnostic or therapeutic procedures.

## **RASF6 Antibody (C-term) Blocking peptide - Protein Information**

Name RASSF6

Function

Involved in the induction of apoptosis, through both caspase- dependent and caspase-independent pathways. May act as a Ras effector protein. May suppress the serum-induced basal levels of NF-kappa-B (By similarity).

**Tissue Location** 

Highest expression in thymus, kidney and placenta. Also detected in colon, small intestine and lung. Tends to be down- regulated in 30-60% of tumors derived from breast, colon, kidney liver, rectum, pancreas, stomach and the thyroid gland compared to the normal counterpart.

#### **RASF6 Antibody (C-term) Blocking peptide - Protocols**

Provided below are standard protocols that you may find useful for product applications.

<u>Blocking Peptides</u>

#### RASF6 Antibody (C-term) Blocking peptide - Images



### RASF6 Antibody (C-term) Blocking peptide - Background

RASSF6 is a member of the RAS association (RA) domainfamily of RAS effectors/tumor suppressors that mediate some of thegrowth inhibitory properties of RAS (see HRAS; MIM 190020)oncogenes (Eckfeld et al., 2004 [PubMed 15574778]).[supplied byOMIM].

### **RASF6 Antibody (C-term) Blocking peptide - References**

Ikeda, M., et al. Sci Signal 2 (90), RA59 (2009) :Hesson, L.B., et al. Mol. Cancer 8, 42 (2009) :Hillian, A.D., et al. Genes Immun. 9(6):501-508(2008)Allen, N.P., et al. Oncogene 26(42):6203-6211(2007)Ikeda, M., et al. Exp. Cell Res. 313(7):1484-1495(2007)